| |
Session I:
Opening Session (joint session with IMPAACT)
|
| |
|
Carl
Dieffenbach |
| |
HPTN 039: A Phase III, Randomized, Double-Blind,
Placebo-Controlled Trial of Acyclovir for the Reduction of HIV
Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative
Persons |
Jim Hughes |
| |
|
|
| |
Session II: State of the Networks
(joint session with IMPAACT)
|
| |
|
Sten Vermund |
| |
|
Brooks Jackson
|
| |
|
|
| |
Session III: Key Trial Achievements (joint session with IMPAACT)
|
| |
|
Nancy
Padian
|
| |
|
Susan
Buchbinder
|
| |
|
Lut Van
Damme
|
| |
|
Robin
Maguire
|
| |
|
Bob
Bollinger
|
| |
Extended
Infant Post-Exposure Prophylaxis with Antiretroviral Drugs
Reduces Postnatal HIV Transmission: PEPI-Malawi (unavailable)
|
Taha Taha
|
| |
Session IV: DAIDS Roles and
Responsibilities (joint session with IMPAACT)
|
| |
|
Ed
Handlesman; Leslie Norwood; Judi Miller; Donna Germuga
|
| |
Session V:
HPTN Trials
|
|
| |
|
Jim Hughes
|
| |
Ethics
Presentation (unavailable)
|
Jeremy
Sugarman
|
| |
|
Janet
Frohlich; Julie Davids
|
| |
|
Ken Mayer
|
| |
|
Audrey
Pettifor
|
| |
|
Steve
Safren
|
| |
HPTN 064:
The Women's HIV Seroincidence Study (ISIS) (unavailable)
|
Sally
Hodder
|